Study Summary
This trial will test a therapy of donated NK cells & chemo for advanced kidney, lung, or bone cancer patients to find the best dose.
- Osteosarcoma
- Mesothelioma
- Kidney Cancer
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: through study completion; an average of 1 year.
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
1 Treatment Group
Chemotherapy and NK Cell Infusion
1 of 1
Experimental Treatment
50 Total Participants · 1 Treatment Group
Primary Treatment: Chemotherapy and NK Cell Infusion · No Placebo Group · Phase 1 & 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18 - 80 · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Are individuals younger than 80 years of age permissible for this experiment?
"As detailed in the eligibility criteria, the patient population for this clinical trial consists of those aged 18 to 80. For patients under 18 and over 65 there are 177 trials and 2,649 trials respectively available." - Anonymous Online Contributor
Are patients able to participate in this research at present?
"As per information on clinicaltrials.gov, this study began recruitment on March 1st 2023 and ceased accepting patients as of January 27th 2023. Although this trial is not accepting applicants currently, there are 2,735 other studies open for enrollment at the moment." - Anonymous Online Contributor
What eligibility criteria must potential participants satisfy to take part in the medical research?
"This medical trial is presently looking for 50 individuals aged between 18 and 80 that are experiencing kidney cancer. Moreover, these patients must meet the following conditions: have given their informed consent to long-term follow up on protocol PA17-0483, possess advanced clear cell renal carcinoma, osteosarcoma or mesothelioma with CD70 expression of 10% in pre-enrollment tumor sample via immunohistochemistry or flow cytometry; fulfil disease specific criteria (see below); be at least 2 weeks from last chemotherapy before lymphodepleting chemotherapy procedure; haven't had any cell therapy for malignancy within" - Anonymous Online Contributor